<DOC>
	<DOCNO>NCT00553020</DOCNO>
	<brief_summary>To assess duration metabolic effect sc inject single dose either insulin glargine ( LantusT ) NPH-insulin ( ProtaphanT ) blood glucose control patient type 2 diabetes</brief_summary>
	<brief_title>Assessment Duration Metabolic Effect Single Bolus sc Injected Lantus Compared NPH Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Type 2 diabetes mellitus either gender define American Diabetes Association ( 3 ) 6 month BMI ( define Appendix A protocol ) 28 kg/mý 32 kg/mý ( implementation Amendment 1 ) 26 kg/mý 34 kg/mý ( implementation Amendment 1 ) Having require treatment insulin least 6 month Stable glycemic control glycohemoglobin ( HbA1c ) &gt; 7.5 % &lt; 9.5 % ( implementation Amendment 1 ) &gt; 7.0 % &lt; 9.5 % ( implementation Amendment 1 Fasting serum Cpeptide &gt; 0.2 pmol/mL . According Amendment 3 , five additional subject `` low '' ( define less equal 0.4 pmol/mL ) 5 subject `` high '' ( define &gt; 0.4 pmol/mL ) fast Cpeptide enrol . Negative pregnancy test female subject childbearing potential ( surgically sterile less 2 year postmenopausal ) begin study No finding medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , muscularskeletal system ) clinically relevant interfere conduct study Normal ECG , blood pressure , pulse rate core body temperature unless investigator consider abnormality clinically irrelevant interfere conduct study Subjects `` brittle '' diabetes predisposition severe hypoglycemia , e.g . 2 severe hypoglycemic episode ( i.e . require assistance another person ) within past year , hospitalization emergency room visit due poor diabetic control within past 6 month Subjects treat insulin total insulin dose &gt; 1.5 IU/kg/day Pregnant nursing woman Female subject childbearing potential ( surgically sterile less 2 year postmenopausal ) unwilling unable use reliable contraceptive measure . Reliable contraceptive measure include follow : systemic contraceptive ( oral , implant , injection ) , diaphragm intravaginal spermicide , cervical cap , intrauterine device , condom spermicide . Any condition require regular use medication regular use medication interfere study conduct Abuse alcoholic beverage ( define Appendix B protocol ) Treatment oral antidiabetic drug within last 4 week Treatment previous 3 month drug know welldefined potential toxicity concern vital organ Symptoms major internal medical disease 4 week study , accord investigator 's opinion , could interfere purpose study History hypersensitivity drug similar chemical structure study drug History presence gastrointestinal , liver , kidney disease condition know interfere absorption , distribution , metabolism , excretion drug Blood donation previous 3 month Positive HIV hepatitis B/Ctest Progressive fatal disease The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>